MarketPulse
A

$ALDX

34 articles found
0 positive
34 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Aldeyra Faces Securities Fraud Suit Over Hidden Trial Data as Stock Plummets 71%

Aldeyra Therapeutics faces securities fraud lawsuit alleging hidden trial data; stock collapsed 71% after FDA's adverse decision on reproxalap.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Aldeyra Therapeutics Hit with Class Action Over Failed Drug; Stock Plummets 70%

Robbins LLP sued Aldeyra Therapeutics over alleged investor misrepresentation regarding failed drug reproxalap. FDA rejected approval; stock fell 70.7%. Lead plaintiff deadline: May 29, 2026.
ALDXclass action lawsuitlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Faces Securities Lawsuit Over Reproxalap Trial Data; May 29 Deadline Looms

Rosen Law Firm files class action against $ALDX over allegedly misleading reproxalap clinical trial statements. Lead plaintiff deadline: May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Aldeyra Therapeutics Faces Securities Fraud Class Action Over Reproxalap Claims

Schall Law Firm launches class action against $ALDX over alleged false statements regarding reproxalap drug candidate. Investors who bought securities Nov 2023-Mar 2026 can join before May 29 deadline.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Therapeutics Faces Securities Class Action Over Reproxalap Trial Disclosures

Rosen Law Firm files securities class action against $ALDX over alleged misleading statements regarding reproxalap clinical trial results. Lead plaintiff deadline set for May 29, 2026.
ALDXsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Aldeyra Faces Class Action Over Reproxalap Trial Claims; Investors Urged to Join Suit

Class action filed against Aldeyra Therapeutics alleging false reproxalap trial data claims; investors from Nov 2023-Mar 2026 may be eligible.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

ALDX Stock Crashes 71% After FDA Rejects Lead Drug; Class Action Lawsuit Filed

Aldeyra Therapeutics stock plummets 71% following FDA rejection of reproxalap for dry eye disease. Class action lawsuit filed; investor deadline May 29, 2026.
ALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Hercules Capital Faces Class Action Over Valuation Disclosure; Investor Deadline Looms

Rosen Law Firm files securities class action against $HTGC alleging false statements on valuations and due diligence. Lead plaintiff deadline: May 19, 2026.
MNDYHCXYHTGCALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Aldeyra Therapeutics Over Misleading Statements

Rosen Law Firm filed a securities class action against Aldeyra Therapeutics for alleged false statements. Affected investors must act by May 29, 2026 to become lead plaintiffs.
MNDYHCXYHTGCALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ImmunityBio Faces Securities Class Action Over Anktiva Misrepresentations

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.
IBRXSLNOALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ALDX Stock Crashes 71% After FDA Rejects Reproxalap; Securities Probe Launched

Aldeyra Therapeutics plummets 71% after FDA rejects lead dry eye drug. Securities litigation firm investigating potential investor claims following efficacy concerns.
ALDXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Aldeyra Stock Plummets 71% After FDA Rejects Lead Drug; Law Firm Launches Investigation

Aldeyra Therapeutics stock plunged 71% after FDA rejected its reproxalap dry eye drug, prompting a securities investigation by Rosen Law Firm.
ITDNOWALDXstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Block & Leviton Llp

Aldeyra Therapeutics Stock Plummets 65% After FDA Rejection; Securities Fraud Investigation Launched

Aldeyra Therapeutics ($ALDX) shares crashed 65% following FDA rejection of reproxalap for dry eye disease. Law firm Block & Leviton investigates potential securities fraud.
EOSENUTXALDXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Aldeyra Stock Plummets 70% After FDA Rejection; Law Firm Eyes Securities Claims

Johnson Fistel investigates Aldeyra Therapeutics after FDA rejects lead drug reproxalap. Stock tumbles over 70% on March 17, 2026 announcement.
ALDXstock declineinvestor losses